News archive
主2024
-
介质释放，介质释放 Novartis NATALEE study shows Kisqali®reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease Kisqali®（ribociclib）to endocrine therapy（ET）demonstrated a28%risk reduction in invasive disease-free survival（iDFS）in subgroup of patients with node-negative（N0）disease at… -
介质释放，介质释放 Novartis Scemblix®Phase III data first to show superior efficicacy with a favorable safety and tolerability简介vs.standard-of-care TKIs in adults with newly diagnosed CML Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results；Scemblix®demonstrated superior MMR rates at week48 vs。… -
介质释放，介质释放 Novartis Phase III data confirm sustained efficy and long-term safety of oral remibrutinib in chronic spontaneous urticaria Patients treated with remibrutinib experienced improvements in weekly urticaria activity scores（UAS7）observed asearly as Week1and sustained to 1year（Week52）1 Remibrutinib， an oral Bruton’s… -
介质释放，介质释放 Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy（IgAN）portfolio In the ALIGN study，atrasentan，in addition to supportive care with a renin-angiotensin system（RAS）inhibitor，demonstrated a statistically significant36.1%proteinuria（… -
介质释放，介质释放 Novartis presents latest Phase III Fabhalta ® （iptacopan）data inC3glomerulopathy（C3G）showing clinically meaningful and statistically significant35.1%proteinuria reduction vs.placebo Secondary endpoint data for estimated glomerular filtration rate（egFR）showed numerical improvement over6months vs.placebo1； additional6-month open-label data to be presented at a future medical… -
介质释放，介质释放 Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR68 per share in cash Novartis secured79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period， reaching the minimum 65%acceptance threshold Settlement of the shares tendered during the… -
介质释放，介质释放 Novartis high lights pioneering innovation in CML with data from Scemblix®Phase III ASC4 FIRST study in newly diagnosed patients at ASCO and EHA Primary results of the Scemblix®ASC4FIRST pivotal Phase III study in first-line Ph+CML-CP supporting third USFDA Breakthrough Therapy designation， ASCO Press Program and the… -
介质释放，介质释放 Novartis enters agreement to acquire Mariana Oncology，strengthening radioligand therapy pipeline Transaction reinforces company’s strategic focus on developing next-generation treatment options for patients living with cancer Mariana Oncology is a preclinical-stage biotechnology company focused…
April2024
-
介质释放，介质释放 地下Venture announce positive efficicacy and safety data for annovel treatment for babies<5kg with malaria There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem®（artemether-lumefantrine）to account for metabolic… -
介质释放，介质释放 Novartis radioligand therapy Lutathera®FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors Approval based on NETTER-Ptrial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric（ages12-17）and adult patients Gastroenteropancreatic… -
关键帧Release Novartis delivers double-digit sales growth and core margin expansion in Q1；FY2024 guidance raised Ad hoc announcement pursuant to Art.53LQ1net sales grew+11%（cc1,+10%USD）with core operating income up+22%（cc，+16%USD）Key growth drivers continued strong sales momentum including… -
关键帧Release Novartis，au premier trimestre:croissanceàdeux chiffres du chiffre d′affaires et expansion de la marge core； hausse des prévisions pour 2024 Annonceévénementielle au sens de l’art。 53RCRésultats du premier trimestre（T1）Chifffre d’affaires net en hausse de+11%（tcc1,+10%USD）et durésultat opérationnel core，de+22%（tcc，+16%USD）…